Vedanta Biosciences Secures $60 Million to Advance Phase 3 Microbiome Therapy VE303 for Recurrent C. difficile Infection
核心洞察
Vedanta Biosciences (搜索) raised $60 million, including a $40 million investment round and $20 million from BARDA, to support its pivotal Phase 3 RESTORATiVE303 trial.
The RESTORATiVE303 study has surpassed 80% enrollment and expects to complete enrollment in H2 2026, with topline efficacy data anticipated in H1 2027.
An independent Data Monitoring Committee recommended the trial continue without modification after efficacy results exceeded the prespecified futility threshold with no significant safety concerns.
Vedanta Biosciences (搜索) has raised $60 million in new funding to advance its lead microbiome-based therapeutic candidate, VE303, through a pivotal Phase 3 clinical trial for the prevention of recurrent Clostridioides difficile infection (搜索) (CDI). The financing extends the company's runway through a critical value-creation milestone as it approaches a potential regulatory submission.
The funding package includes a $40 million investment round led by existing backers AMR Action Fund (搜索) and BNP Paribas Asset Management Alts (搜索), with approximately $18 million funded during the first quarter and an additional $22 million in the second quarter. Vedanta also received $20 million under its existing contract with the Biomedical Advanced Research and Development Authority (搜索) (BARDA), bringing total new funding to $60 million.
RESTORATiVE303 Trial Design and Progress
The RESTORATiVE303 study is a randomized, double-blind, placebo-controlled global trial enrolling patients at more than 150 clinical sites across approximately 20 countries. The trial recently surpassed 80% enrollment, and Vedanta expects to complete patient enrollment during the second half of 2026, with topline efficacy data anticipated in the first half of 2027.
Participants are randomized on a two-to-one basis to receive a 14-day course of VE303 or matching placebo. The primary endpoint measures the recurrence rate of CDI at eight weeks. The study is designed to evaluate whether VE303 can reduce recurrence rates in patients at high risk of developing repeat CDI following antibiotic treatment and is intended to support a future Biologics License Application with the U.S. Food and Drug Administration.
Earlier this year, the independent Data Monitoring Committee overseeing the trial completed its first planned interim review and recommended the study continue without modification. The committee concluded that efficacy results exceeded the predefined futility threshold while identifying no significant adverse events or new safety concerns, allowing the registrational study to proceed as planned.
VE303: A Defined Microbiome Therapeutic
VE303 is an orally administered live biotherapeutic product composed of a defined consortium of eight bacterial strains developed to restore the gut microbiome and prevent recurrent CDI. Unlike microbiome therapies derived from donor fecal material, VE303 is manufactured from standardized clonal bacterial cell banks designed to deliver a consistent product. The FDA granted VE303 Orphan Drug Designation in 2017 and Fast Track Designation in 2023.
Leadership Expansion
In connection with the financing, Vedanta expanded its Board of Directors with the appointments of Manos Perros, Ph.D., as Executive Chairman and Andrew Davis as an independent director. Perros brings more than three decades of pharmaceutical R&D experience, having most recently served as CEO of Entasis Therapeutics, where he oversaw the development of Xacduro, an FDA-approved treatment for Acinetobacter baumannii pneumonia. He previously held senior leadership roles at AstraZeneca, Novartis, and Pfizer.
Davis brings more than 20 years of experience in business development, mergers and acquisitions, and commercial strategy. He currently serves as Chief Business and Strategy Officer at Convergent Therapeutics and previously held senior executive positions at Dynavax, Ironwood Pharmaceuticals, iNova Pharmaceuticals, and Bausch Health.
Bernat Ollé, Ph.D., founder and Chief Executive Officer of Vedanta Biosciences (搜索), stated: "We are grateful to our shareholders and BARDA for their continued support and pleased to welcome Manos and Andrew to the Vedanta Board of Directors. Manos and Andrew bring a wealth of experience in development and regulatory approval of innovative drugs as well as execution of strategic transactions."
Addressing an Unmet Medical Need
Recurrent C. difficile infection remains a significant public health challenge, affecting a substantial number of patients after an initial infection and contributing to prolonged hospitalizations, increased healthcare costs, and reduced quality of life. By advancing VE303 through late-stage development, Vedanta is seeking to address an area of persistent unmet medical need while expanding the emerging field of microbiome-based therapeutics.